Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2023 | The future of gastric cancer treatment beyond ESMO 2023

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the future of gastric cancer treatment, highlighting the need for a target beyond HER2 considering the current standard of care. Efforts should be made to improve outcomes for patients who are PD-1 low and therefore not suitable for immunotherapies. MET and EGFR targeted therapies are showing preliminary efficacy and emerging biomarkers such as lysyl-tRNA Synthetase (KRS) and Claudin18.2 are promising. Transcriptome analyses are being conducted to assess the use of antibody-drug conjugates (ADCs); despite difficulties, the outlook is still bright for the future of gastric cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.